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Characteristics of Hospitalized Children with 2009 Pandemic 
Influenza A (H1N1): A Multicenter Study in Korea 
The majority of Korean patients with pandemic influenza A (H1N1) during the 2009 
epidemic were under 20 yr of age. The limited data on the clinical characteristics of these 
children led us to conduct a case note-based investigation of children admitted to  
6 university hospitals with 2009 H1N1 influenza. A total of 804 children was enrolled. The 
median age was 5 yr; 63.8% were males; and 22.4% had at least one chronic underlying 
disease. Ninety-five of the patients (11.8%) were critically ill and they suffered more from 
shortness of breath, dyspnea and lymphopenia than the other patients. Among all the 
patients, 98.8% were treated with antivirals and 73% received treatment within 48 hr of 
illness onset. All the enrolled patients are alive and appear to have had good outcomes, 
probably due to the early intervention and antiviral treatment. This study deals with 
hospitalized children whose diagnoses of influenza A (H1N1) were confirmed, and 
therefore provides important new information about the clinical patterns of children with 
influenza A (H1N1) in Korea. 
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INTRODUCTION
In the middle of April 2009, influenza caused by the novel A 
(H1N1) strain of influenza virus of swine origin was reported in 
Mexico and California. On April 24 the World Health Organiza-
tion (WHO) announced the emergence of a novel influenza 
strain, and the infection was declared a pandemic in June (1). 
The first reported pandemic influenza A (H1N1) case in Korea, 
occurred in an adult who had visited Mexico in May 2009, and 
the infection spread into the community as an epidemic there-
after (2). 
  Clinical aspects of the children hospitalized with the novel A 
(H1N1) influenza have been reported in many countries, but 
patients’ ages, rates of admission to intensive care units (ICU), 
and mortality, differed markedly depending on the study period, 
subjects and geographic region (3-10). Thus, for example, there 
was a distinct difference between Korea and USA. In Korea, the 
highest incidence of H1N1 virus infection occurred in young 
people aged 0 to 19 yr, but mortality was greatest among those 
over 60 yr; in the USA, incidence and mortality were highest in 
individuals aged 17 to 64 (2, 11). Moreover data on the impact 
of influenza A (H1N1) on Korean children are limited; the exist-
ing reports concern only patients with severe symptoms or deal 
with small numbers of cases in single institutions, or cover only 
the beginning of the outbreak. No study has yet appeared of 
children hospitalized with A (H1N1) influenza over the entire 
outbreak from 2009 to 2010 (12-14).
  In this study, our objective was to describe the demographic 
characteristics, epidemiology, clinical manifestations, treatment 
and clinical course of children admitted to six Korean university 
hospitals with pandemic A (H1N1) influenza. This study allows 
us to identify the clinical features of infected children in a coun-
try where the rate of 2009 influenza A (H1N1) was high but mor-
tality was low. 
MATERIALS AND METHODS
We studied patients under 18 yr of age who were admitted to 
five capital region university hospitals, and one university hos-
pital in Jeju-do, with influenza A (H1N1) virus infection during 
the 6 months between August 20, 2009 and January 30, 2010. 
Demographic and epidemiologic data, clinical manifestations, 
laboratory and radiologic findings, treatment and clinical course, 
were abstracted retrospectively from medical records on stan-Ko JH, et al.  •  Children with Pandemic Influenza A (H1N1)
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dardized case report forms. Cases of influenza A (H1N1) were 
confirmed by testing specimens collected from the oropharynx 
or nasopharynx with sterile swabs or aspirates using the influ-
enza A (H1N1) real time reverse transcriptase-polymerase chain 
reaction (RT-PCR). Each hospital performed RT-PCR using       
AccuPower New Inf A (H1N1) & Inf A Real-Time RT-PCR (Bi-
oneer Inc., Daejeon, Korea), Real-QTM H1N1 Novel One-step 
kits (Biosewoom., Inc., Seoul, Korea) and AdvanSure Influenza 
A/Influenza A (H1N1) (2009) real-time RT-PCR (LG Life Sci-
ences Inc., Seoul, Korea) kits.
  Children above 2 yr were defined as obese when a formula 
placed their body mass index at or above the 95th percentile on 
government charts specifying age and gender (15). Patients who 
required ventilator care or admission to an intensive care unit 
(ICU) were defined as critically ill patients. Full recovery meant 
that patients became free from symptoms and complications 
associated with influenza A (H1N1). We used laboratory values 
in the normal range for patients’ ages (16). The study protocol 
was approved by the institutional review board (IRB) of Hanyang 
University Hospital. Informed consent was waived by the board. 
Data were entered on Microsoft Excel spreadsheets and trans-
ferred to SPSS 17.0 (SPSS Inc, Chicago, IL, USA) and SAS 9.1 for 
further analysis. Data were analyzed using the chi-square test, 
Fisher’s exact test, the independent t-test or multiple logistic re-
gression, and statistical significance was set at P < 0.05.
RESULTS
Demographic and epidemiologic characteristics
Between August 20, 2009 and January 30, 2010, 827 patients 
were admitted with influenza A (H1N1) to the 6 hospitals. Of 
these, 23 were positive in the influenza A (H1N1) rapid antigen 
test but negative for influenza A (H1N1) RT-PCR. Consequent-
ly, 804 patients were enrolled in the study. The first hospitaliza-
tions for influenza A (H1N1) occurred in week 34, 2009, when 
the government started to operate the designated hospital sys-
tem which included the six study hospitals. Cases began to in-
crease in week 38 and peaked in week 44 at a total of 119 cases; 
at this point the government initiated its vaccination strategy. 
Thereafter new cases declined steadily (Fig. 1). 
  The mean age of the patients was 5 yr (range 0-18 yr). Thirty-
eight (4.7%) were less than 6 months old, 100 (12.5%) were 7-23 
months old, 271 (33.7%) were 2-5 yr old, 347 (43.2%) were 6-12 
yr old and 48 (6.0%) were over 13 yr old (Table 1). 
  Of the 804 patients, 512 (63.8%) were boys and 291 (36.2%) 
girls. There were more boys than girls at all ages, particularly in 
the 2-5 yr group and the 6 yr and over groups, and this difference 
was statistically significant (Fig. 2). Of the patients, 7.7% (45/582) 
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Fig. 1. Weekly distribution of 
children hospitalized with influ-
enza A (H1N1) in 6 university 
hospitals from August 2009 to 
January 2010 in Korea. The first 
day of 34th week of year 2009 is 
August 16, 2009, and the first 
study patient developed the ill-
ness on August 20, 2009.
Table 1. Epidemiology and underlying diseases in patients hospitalized with influenza 
A (H1N1) in 6 university hospitals from August 2009 to January 2010 in Korea
Characteristics No. (%)
Age (yr), median (range)
   0-6 month
   7-23 month
   2-5 yr
   6-12 yr
   ≥ 13 yr
5 (0-18)
38 (4.7)
100 (12.5)
271 (33.7)
347 (43.2)
48 (6.0)
Sex
   Male
   Female
 
512 (63.8)
291 (36.2)
Health status
   No underlying condition 
   Underlying condition 
      Asthma
      Other chronic lung diseases 
      Hemato-oncologic diseases
      Seizure
      Chronic heart or circulatory disease
      Neurologic diseases
      Immunosuppressive condition (HIV, steroid)
      Kidney diseases
      Other metabolic diseases
      Musculoskeletal diseases
      Others 
 
624 (77.6)
180 (22.4)
84 (46.7) 
20 (11.1) 
16 (8.9 )
16 (8.9 )
12 (6.7) 
9 (5.0) 
5 (2.8)
4 (2.2) 
1 (0.6) 
1 (0.6) 
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had been vaccinated against influenza A (H1N1), and 22.5% 
(91/403) against Streptococcus pneumoniae. Eighty seven (11%) 
of 785 patients had received oseltamivir less than 14 days prior 
to the study period. The proportion of the children with at least 
one underlying health condition was 22.4% (180/804). Respira-
tory disorders (57.8%) including asthma (n = 84, 46.7%) and 
other chronic lung diseases (n = 20, 11.1%) were the most com-
mon; neurologic disorders (n = 25, 13.9%) including seizure 
were next, followed by hemato-oncologic disease (n = 16, 8.9%), 
chronic heart or circulatory disease (n = 12, 6.7%) and kidney 
disease (n = 4, 2.2%) (Table 1).
Clinical manifestations and laboratory findings 
Seven hundred and thirty-five (95.6%) of the 769 patients admit-
ted with influenza A (H1N1) complained of fever, and in fact, 
556 patients (72.3%) had fevers when their temperatures were 
taken. The next most common symptoms were cough (n = 726/ 
798, 91%), rhinorrhea (n = 469/791, 59.3%), vomiting (n = 252/ 
782, 32.2%), sore throat (n = 207/762, 27.2%), dyspnea (n = 202/ 
750, 26.9%), shortness of breath (n = 193/778, 24.8%), sneezing 
(n = 130/773, 16.8%), diarrhea (n = 93/781, 11.9%), myalgia (n =  
45/773, 5.8%), seizure (n = 35/778, 4.5%), chest pain (n = 32/766, 
4.2%), mental drowsy or change (n = 15/775, 1.9%), arthralgia 
(n = 7/772, 0.9%), conjunctivitis (n = 6/777, 0.8%) and epistasix 
(n = 4/771, 0.5%). Five of the patients with seizure, had febrile 
seizure and nine patients had both seizure and mental change. 
Fever and cough were the most common symptoms in all age 
groups. The patients with rhinorrhea and diarrhea were on av-
erage younger, and those with shortness of breath, dyspnea, chest 
pain, sore throat, headache, myalgia and nausea were older, 
while the proportion of patients with fever did not differ signifi-
cant according to age, but the fevers lasted longer in the young-
er age groups. Sneezing, conjunctivitis, epistaxis, mental drows-
iness or change and arthralgia did not differ significantly be-
tween age groups (Table 2).
  Mean white-cell count was 9,170 ± 4,582/μL (range 30-28,610), 
with leukopenia in 135/804 (16.8%) and leukocytosis in 88/804 
(11%), and mean lymphocyte count was 1,991 ± 2,120/μL (range 
0-25,050). Lymphopenia was observed in 452/804 (56.2%). Mean 
platelet count was 247,000 ± 82,000/μL (range 5,000-828,000/
μL), with thrombocytopenia in 53/795 (6.7%) and thrombocy-
tosis in 33/804 (4.1%). Six hundred and twenty-three (77.5%) of 
the 804 patients were positive for C-reactive protein (CRP), and 
mean CRP was 3.47 ± 3.6 mg/dL. Abnormalities in chest radio-
graphs were detected in 525 (72.5%) of 724 patients. The most 
common abnormalities were bronchopneumonia (n = 387, 
74.3%), followed by lobar pneumonia (n = 74, 14.2%), intersti-
tial pneumonia (n = 18, 3.5%) and alveolar pneumonia (n = 4, 
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Fig. 2. Age and sex distribution of hospitalized children.
Table 2. Symptoms and clinical course according to age in Korean patients hospitalized with influenza A (H1N1)
Age (yr) Total (%) (n = 803) < 2 (n = 137) 2-5 (n = 271) > 5 (n = 395) P value
Fever
   duration (mean ± SD)
735/769 (95.6)
2.8 ± 1.8
129/135 (95.6)
3.2 ± 2.1
244/256 (95.3)
3.0 ± 1.9
362/378 (95.8)
2.5 ± 1.6
0.972
0.022
† 
Cough 726/798 (91.0) 112/136 (82.4) 252/270 (93.3) 362/392 (92.3) 0.001
Rhinorrhea 469/791 (59.3) 99/134 (73.9) 173/266 (65.0) 197/391 (50.4) < 0.001
Sore throat 207/762 (27.2) 13/129 (10.1) 59/256 (23.0) 135377 (35.8) < 0.001
Shortness of breath 193/778 (24.8) 13/133 (9.8) 55/263 (20.9) 125/382 (32.7) < 0.001
Dyspnea 202/750 (26.9) 12/129 (9.3) 54/254 (21.3) 136/367 (37.1) < 0.001
Chest pain 32/766 (4.2) 1/126 (0.8) 6/258 (2.3) 25/382 (6.5) 0.003*
Vomiting 252/782 (32.2) 42/133 (31.6) 98/261 (37.5) 112/388 (28.9) 0.066
Diarrhea 93/781 (11.9) 36/133 (27.1) 25/262 (9.5) 32/386 (8.3) < 0.001
Nausea 81/781 (10.4) 2/133 (1.5) 25/261 (9.6) 54/387 (14.0) < 0.001
Headache 88/764 (11.5) 1/127 (0.8) 19/255 (7.5) 68/382 (17.8) < 0.001*
Seizure 35/778 (4.5) 11/133 (8.3) 10/259 (3.9) 14/386 (3.6) 0.074
Myalgia 45/773 (5.8) 2/129 (1.6) 11/257 (4.3) 32/387 (8.3) 0.007* 
Antiviral treatment
   days from onset of symptoms (mean ± SD)
791/801 (98.8)
2.46 ± 4.82
133/137 (97.1)
3.87 ± 8.24 
267/271 (98.5)
2.23 ± 2.72
391/393 (99.5)
2.14 ± 4.26
0.08
0.001
†
Pneumonia 526/750 (70.1) 72/129 (55.8) 172/248 (69.4) 282/373 (75.6) < 0.001 
ARDS 7/796 (0.9) 0/136 (0.0 ) 2/269 (0.7) 5/391 (1.3) NA
CNS involvement 9/737 (1.2) 2/124 (1.6) 3/252 (1.2) 4/361 (1.1) 0.819*
Chi-square test. *Fisher’s exact test; 
†Independent t-test. ARDS, acute respiratory distress syndrome; NA, not available; CNS, central nervous system.Ko JH, et al.  •  Children with Pandemic Influenza A (H1N1)
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0.8%) (Table 3).
Treatment and clinical course
Five hundred and twenty-six (70.1%) of the 750 patients had 
pneumonia, 7/796 (0.9%) had acute respiratory distress syn-
drome (ARDS) and 9/737 (1.2%) had central nervous involve-
ment. The proportion of patients with pneumonia and ARDS 
was higher among the older age groups (Table 2). The mean  
interval between symptom onset and hospitalization was 1.89 
days (median, 1 day). Antiviral use was reported in 791/801 
(98.8%) patients, and oseltamivir and zanamivir were given to 
776/787 (98.6%) and 11/787 (1.4%) patients, respectively. Mean 
time from onset of symptoms to start of antiviral treatment was 
2.5 days (median, 1 day) and 570 (73%) of the 783 patients were 
given an antiviral within 48 hr after onset of illness (Table 4) and 
this interval was shorter in older patients than in younger ones 
(Table 2).  
  Ninety-two (12%) of the 764 patients taking oseltamivir re-
ported one or more side effects. The most frequently reported 
symptom overall was vomiting (n = 61, 66.3%), followed by nau-
sea (n = 24, 26.1%), diarrhea (n = 23, 25%), skin rash (n = 6, 6.5%) 
and headache (n = 3, 3.3%). There were no differences in side 
effects between the age groups. 
  Of the 798 patients, 654 (82%) had been treated with antibac-
terial agents for associated diseases: 568/642 (88.5%) for pneu-
monia-suspected bacterial infection, 51/642 (7.9%) for sinusitis, 
acute otitis media and pharyngotonsilitis, and 16/642 (2.5%) for 
other bacterial diseases such as urinary tract infection. Of the 
Table 3. Laboratory findings in patients hospitalized with influenza A (H1N1)
Characteristics  Findings
Laboratory items
   Leukocyte count
       Mean count-per µL (mean ± SD)
       Leukopenia, No./Total No. (%)
       Leukocytosis, No./Total No. (%)
   Lymphocyte count
       Mean count-per µL (mean ± SD)
       Lymphopenia, No./Total No. (%)
   Platelet count
       Mean count-per µL (mean ± SD)
       Thrombocytopenia ( < 150.000/µL), No./Total No. (%)
       Thrombocytosis ( > 400,000/µL), No./Total No. (%)
   C-reactive protein ( > 0.3 mg/dL), No./Total No. (%)
       Mean* ± SD
  
 
   9,170 ± 4,582
135/804 (16.8)
  88/804 (11.0)
 
   1,991 ± 2,120 
452/804 (56.2)
 
 247,000 ± 82,000
53/795 (6.7)
33/804 (4.1)
623/804 (77.5)
 3.47 ± 3.6
Chest radiographic findings, No./Total No. (%)
   Abnormal findings 
       Bronchopneumonia
       Lobar pneumonia
       Interstitial pneumonia
       Alveolar pneumonia
       Pleular effusion
       Pneumothorax
       Pneumomediastinum
       Others
   Normal findings
  
525/724 (72.5)
387/521 (74.3)
  74/521 (14.2)
18/521 (3.5)
  4/521 (0.8)
  2/521 (0.4)
  2/521 (0.4)
  2/521 (0.4)
32/521 (6.1)
199/724 (27.5)
*CRP greater than 0.3 mg/dL was considered positive.
Table 4. Treatment strategies for patients hospitalized with influenza A (H1N1)
Characteristics  Findings
Antiviral treatment, No./Total No. (%)
   Oseltamivir
   Zenamivir
   ≤ 2 days after onset of symptom
   Days from onset of symptom (mean ± SD)
791/801 (98.8)
776/787 (98.6)
11/787 (1.4)
570/783 (73)
2.45 ± 4.8
Adverse effects*, No./Total No. (%)
   Vomiting
   Nausea
   Diarrhea
   Skin rash & allergic reaction
   Headache
   Dizziness
   Epistaxis
   Cough & respiratory symptoms
   Confusion & behavior change
   Red eye
   Sleep disorder
92/764 (12.0)
61/92 (66.3)
24/92 (26.1)
23/92 (25.0)
6/92 (6.5)
3/92 (3.3)
2/92 (2.2)
1/92 (1.1)
1/92 (1.1)
1/92 (1.1)
-
-
Antibiotic treatment, No./Total No. (%)
   Pneumonia
   Sinusitis, acute otitis media, acute pharyngotonsillitis
   Other diseases
†
654/798 (82.0)
568/642 (88.5)
51/642 (7.9)
16/642 (2.5)
Use of mechanical ventilator, No./Total No. (%)
   Duration of mechanical ventilation (days)
      Median (range)
      Mean ± SD
47/798 (5.9)
2 (1-10)
    3 ± 2.1
Admission to ICU, No./Total No. (%)
   Duration of ICU stay (days)
      Median (range)
      Mean ± SD
57/799 (7.1)
4 (1-21)
 5.1 ± 3.3
Hospital days (mean ± SD)  4.7 ± 3.9
Duration from onset to full recovery (days) (mean ± SD)  7.2 ± 6.4
*Patients were treated with oseltamivir; 
†Urinary tract infection, meningitis, etc.
total patients, 40 (5.7%) were confirmed to have Mycoplasma 
pneumonia as well as influenza A (H1N1).
The mean time from symptom onset to full recovery was 7.2 ±  
6.4 days. The mean duration of ventilator care in the 47/798 (5.9%) 
patients who received ventilator care was 3 ± 2.1 days, and the 
mean duration of ICU hospitalization in the 57/799 (7.1%) pa-
tients admitted to the ICU was 5.1 ± 3.3 days. Patients who re-
quired ventilator care or ICU admission totaled 95 (11.8%). 
These patients were classified as critically ill, and the others as 
not critically ill. All the patients recovered completely without 
complications (Table 4). 
We undertook an analysis of the relationships between days 
from onset of symptoms to date of antiviral treatment, and days 
from symptom onset to full recovery, using Pearson’s correla-
tion coefficients. The correlation coefficient was about 0.754 and 
there was a strong positive correlation between the two variables 
(P < 0.001).
Comparison between critically ill patients and not critically 
ill patients 
The mean ages of the critically ill patients and not critically ill 
patients were 6.7 and 5.5 yr, respectively (P = 0.004). More of 
the patients with underlying health conditions were critically ill Ko JH, et al.  •  Children with Pandemic Influenza A (H1N1)
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patients (40% vs 20.2%, P < 0.001). There was no significant dif-
ference in obesity. The mean duration of fever was shorter in 
the critically ill patients (2.4 days vs 2.8 days, P = 0.017). More of 
the critically ill patients complained of shortness of breath and 
dyspnea, and fewer suffered from rhinorrhea, sneezing, sore 
throat and diarrhea (P < 0.03). There was no significant differ-
ence in frequency of pneumonia or central nervous involvement, 
but 7.5% of the critically ill patients suffered from acute respira-
tory distress syndrome (ARDS) compared to none of the not 
critically ill patients (Table 5).
  The critically ill patients had higher scores than the others in 
the following laboratory tests; leukocytosis 28.4% vs 8.5% (P <  
0.001), lymphopenia 81.1% vs 52.7% (P < 0.001), and mean CRP 
4.4 mg/dL vs 2.8 mg/dL (P = 0.003). There were no significant 
differences between the two groups in frequency of antiviral 
use and interval from symptom onset to initiation of antiviral 
treatment, but more of the critically ill patients received antivi-
ral treatment in less than 2 days (84.2% vs 71.2%, P = 0.008). 
Also more of the patients receiving antibacterial agents were 
critically ill patients (99% vs 79.7%, P < 0.001) and their average 
length of hospital stay was greater (6 days vs 4.5 days, P = 0.013), 
but times from onset to full recovery did not differ significantly.
  When we compared rates of lymphopenia in the critically ill 
patients and the not critically ill patients by age group, we found 
Table 5. Comparison between critically ill patients and not-critically ill patients
Parameters
Critically ill 
(n = 95)
Not-Critically ill 
(n = 704)
P value
Univariate Multivariate
‡ 
Age (mean ± SD)   6.7 ± 3.6   5.5 ± 4.0 0.004
† 0.308 
Sex (male) 65 (68.4) 444 (63.1) 0.309
Obesity, No. (%) 3/87 (3.5) 39/575 (6.8) 0.344*
Health status, No. (%)
   Healthy
   Underlying condition
 
57 (60.0)
38 (40.0)
 
562 (79.8)
142 (20.2)
 
< 0.001
 
 
0.074 
Fever duration (mean ± SD)   2.4 ± 1.6   2.8 ± 1.9 0.008
†  0.331 
Symptoms, No./Total No. (%)
   Cough
   Rhinorrhea
   Sneezing
   Sore throat
   Shortness of breath
   Dyspnea
   Chest pain
   Vomiting
   Diarrhea
   Nausea
   Headache
   Seizure
   Mental drowsy or change
   Myalgia
 
85/95 (89.5)
43/95 (45.3)
6/94 (6.4)
15/92 (16.3)
32/94 (34.0)
53/94 (56.4)
6/92 (6.5)
23/95 (24.2)
4/94 (4.3)
10/95 (10.5)
6/94 (6.4)
4/94 (4.3)
2/93 (2.2)
3/94 (3.2)
 
637/699 (91.1)
424/692 (61.3)
123/676 (18.2)
189/666 (28.4)
159/680 (23.4)
147/652 (22.6)
26/670 (3.9)
227/683 (33.2)
88/683 (12.9)
71/682 (10.4)
80/666 (12.0)
31/680 (4.6)
13/679 (1.9)
42/675 (6.2)
 
0.598
0.003
0.004
0.014
0.025
< 0.001
0.262*
0.078
0.015
0.972
0.107
1.000*
0.700*
0.241
  
  
0.323 
0.007 
0.129 
0.001 
< 0.001
  
   
0.101 
Clinical course, No./Total No. (%)
   Pneumonia
   ARDS
   CNS involvement
  
69/93 (74.2)
7/93 (7.5)
2/91 (2.2)
   
453/653 (69.4)
0/699 (0.0)
7/642 (1.1)
  
0.343
NA
0.310*
  
Leukocyte count, Mean count-per µL (mean ± SD)
   Leukopenia, No./Total No. (%)
   Leukocytosis, No./Total No. (%)
   11,776 ± 5,963.7
11/95 (11.6)
27/95 (28.4)
  8,833.6 ± 4,217.2
121/704 (17.2)
60/704 (8.5)
< 0.001
†
0.167
< 0.001
0.014 
  
0.516 
Lymphocyte count, Mean count-per µL (mean ± SD)
   Lymphopenia, No./Total No. (%)
  1,085.2 ± 1,081.5
77/95 (81.1)
 2,121.8 ± 2,199.3
371/704 (52.7)
< 0.001
†
< 0.001
 
0.005 
Platelet count, Mean count-per µL (mean ± SD)
   Thrombocytopenia (< 150.000/µL), No./Total No. (%)
   Thrombocytosis (> 400,000/µL), No./Total No. (%)
253.9 ± 82.3
4/95 (4.2)
5/95 (5.3)
245.3 ± 81.7
49/697 (7.0)
28/704 (4.0)
0.338
†
0.302
0.579
 
 
 
C-reactive protein (> 0.3 mg/dL) (mean ± SD)   4.4 ± 4.7   2.8 ± 3.3 0.003 0.286 
Antiviral treatment, No. (%)
   Oseltamivir
   Zenamivir
   ≤ 2 days after onset of symptom, No./Total No. (%)
   Days from onset of symptom day (mean ± SD)
 
95 (100.0)
0 (0.0) 
80/95 (84.2)
  2.3 ± 4.6
 
678 (98.4)
11 (1.6)
490/688 (71.2)
  2.6 ± 4.9
 
0.378*
 
0.008
0.587
†
 
 
 
0.194 
Antibiotic treatment, No./Total No. (%) 94/95 (99.0) 558/700 (79.7) < 0.001 0.997 
Hospital days (mean ± SD)   6.0 ± 5.6   4.5 ± 3.6 0.013
† 0.156 
Duration from onset to full recovery (mean ± SD)   7.4 ± 6.7   7.2 ± 6.3 0.726
†
Chi-square test; *Fisher’s exact test; 
†Independent t-test; 
‡Factors significant (P < 0.05) in univariate analysies were submitted to multiple logistic regression analysis. ARDS, 
acute respiratory distress syndrome; NA, not available; CNS, central nervous system.Ko JH, et al.  •  Children with Pandemic Influenza A (H1N1)
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no significant difference in the group of under 2 yr (25% vs 10.1%), 
but significant differences in the 2-5 yr (72.7% vs 42.5%, P =  
0.006) and 6-12 yr (90.8 % vs 77.1%, P = 0.013) groups .
  Factors that were significantly associated (P < 0.05) with the 
critically ill patients in univariate analyses were put into a full 
model for multiple logistic regression analysis. Shortness of 
breath, dyspnea, leukocytosis and lymphopenia were found to 
be positively associated with critical illness, while sneezing was 
negatively associated with critical illness.
DISCUSSION
In 2009 the influenza A (H1N1) virus infection became a full-
scale pandemic, and Korea was among the countries severely 
affected. In this study we sought to assess the clinical patterns 
of children who were confirmed with H1NI infection and treat-
ed in six university hospitals.
  In 2009, when the H1N1 virus infection swept the country, a 
total of 760,000 patients diagnosed with the infection were re-
ported to the Korea Centers for Disease Control and Prevention 
(KCDC), 72% of whom were aged 0 to 19 yr (2). According to a 
report by the US Centers for Disease Control and Prevention, of 
the total number of individuals infected with the H1N1 virus, 
32% were children aged 0-17 yr in the USA; in the UK, 41% were 
aged 0-14 yr; and in Japan, 59% were aged 0-15 yr. Thus, the pro-
portion of infections occurring among children was higher in 
Korea than in these other countries (11, 17, 18).
  The median age of the Korean patients was 5 yr, similar to the 
4.8-6.0 yr in reports on child patients in other countries. Excep-
tions were Argentina with a median age of 10 months, and In-
dia with a median age of 2 yr (3-10).
  The first of the patients in our study conducted from August 
20, 2009 to January 30, 2010 was seen in the 34th week of 2009 
and the peak occurred in the 44th week. The corresponding 
times in the KCDC data pertaining to all influenza A (H1N1) 
patients throughout the country were the 18th and 44th week of 
2009, respectively (2, 19, 20). 
  Over the period of our study, both the first reported patient 
and the peak of infections were earlier in the age groups above 
6 yr than in those below 6 yr. In addition, according to the KCDC 
report, the 10-19 yr age group began to be infected earlier, fol-
lowed by the 0-9 yr group and those above 20 yr of age. Accord-
ingly, it can be assumed that Korea’s 2009 influenza A (H1N1) 
virus pandemic affected first those who returned from overseas 
trips, and the contagion then spread to school children and ad-
olescents (2, 20).
  The main symptoms of our child patients were similar to those 
of the influenza A (H1N1)-virus-infected patients in other coun-
tries. More of the younger patients suffered diarrhea and rhi-
norrhea, whereas more of the older patients suffered headache, 
sore throat, cough, dyspnea, chest pain, myalgia, and nausea 
(3-10).
  As in previous studies, the fact that younger patients experi-
enced more instances of diarrhea suggests that in young chil-
dren the virus actively proliferates in the gastrointestinal tract as 
well as in the respiratory system. According to Yoo et al. (21), 
however, there was no statistically significant relationship be-
tween patient age, frequency of occurrence of gastrointestinal 
symptoms, and detection of H1N1 in feces. For rhinorrhea, the 
general finding is that the symptom is more common in young-
er children. In view of the higher viral load in younger patients 
and the longer period of shedding in patients with lowered im-
munity reported in previous studies, it is possible that patients’ 
immunity, rather than virus proliferation itself, affects virus loads 
and symptoms (22).
  According to reports from other countries, critically ill patients 
were older than those who were not critically ill (6, 23). We con-
sidered the possibility that younger patients were treated earli-
er, but actually the average time from symptom onset to initia-
tion of antiviral agents in the younger patients was longer, and 
fewer of them received prescriptions within two days of the on-
set of illness. Probably younger children mounted weaker im-
mune reactions, whereas school children, other adolescents, 
and young adults, had strong immune reactions. Moreover more 
of the older children developed excessive inflammation due to 
the virus, experienced pneumonia and serious complications 
such as ARDS and post-infectious encephalitis, were admitted 
to the ICU, and suffered death. Similarly more of the older pa-
tients in our study developed pneumonia, and suffered from 
ARDS and neurologic diseases, although the numbers of such 
cases were too small for statistical significance.
  Interestingly, we found that duration of fever was significant-
ly shorter in the critically ill patients, and that significantly more 
of these patients were prescribed antiviral drugs within two days 
of the onset of illness. In the Colorado study, fever or non-fever 
and duration of fever were unrelated to the probability of hospi-
talization of patients in wards or intensive care units, which also 
suggests that the extent of fever may not be directly relevant to 
disease severity (23).
  Obesity was not found to be a risk factor in the child patients 
in this study, which was also the case in the Colorado research, 
but obesity was reported to be a risk factor in adults (23, 24).
  Lymphopenia is known to occur in influenza virus infections, 
and we found that it was more common in the critically ill pa-
tients. This difference was not apparent in the below 2 yr group, 
but was clear in the 2-6 yr and above 6 yr groups. This is consis-
tent with a report that lymphopenia develops more often in older 
patients (14). It also suggests that, since cytokine secretion var-
ies according to age in influenza virus-infected patients, there is 
a difference in the extent of cell death with patient age, and that 
in children over 2 yr, with mature immune systems, differences 
in individual immune reactions may influence the occurrence Ko JH, et al.  •  Children with Pandemic Influenza A (H1N1)
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of lymphopenia, and in turn the severity of disease (25, 26) .
  In our study, 11.8% of the patients were hospitalized in the 
ICU, but none of them died; and mortality in the KCDC’s 0-19 
yr group was only 0.005% (25/552,786). These figures reveal that 
Korea’s highly contagious influenza A (H1N1) virus infection 
was not in fact very severe (2). This is substantially different from 
Argentina’s reported ICU hospitalization rate of 19% and mortal-
ity of 5%, but similar to Japan’s reported mortality of 0.00003% 
(38/1,220,000) for the below 15 yr group. These low rates are 
presumably due to accessibility of medical care and early admin-
istration of antiviral drugs. The proportion of cases receiving 
antiviral drugs within two days of the onset of illness was 73% in 
the present study and 88.9% in Japan, whereas in Argentina it 
was 12.5%, a marked difference. This suggests that mortality 
and critical illness was rare in young Korean children, presum-
ably because of the early diagnosis and early administration of 
antiviral drugs (18, 27).
  The frequency of side effects of the antiviral drugs used in this 
study was 12%, much lower than the 41%-53% in other studies. 
This could be due to preventive drug administration versus ther-
apeutic drug administration, outpatient versus inpatient treat-
ment, and interview-based surveys vs questionnaire-based sur-
veys. The same frequent side effects were reported, however: 
mainly gastrointestinal symptoms such as nausea, vomiting, and 
diarrhea, followed by headache, insomnia, and psychoneurotic 
symptoms such as changes in emotions and behavior (28-30).
  Oseltamivir, which had not been frequently used in young 
children, especially in those below 12 months, was widely used 
in this major epidemic, and this paved the way for further use 
of the drug. The data showed that oseltamivir has infrequent and 
mild side effects, and that when administered early it reduces 
the severity of disease, which suggest that it can be used to treat 
young children in a serious outbreak of influenza. 
  One limitation of this study was the small number of research 
institutions that participated; this led to inconsistent treatment 
and process observation. Hence, since Korea offers good access 
to medical care and Koreans prefer hospital treatment, the se-
verity of the symptoms of the hospitalized patients may have 
been lower than in the public as a whole. Another limitation 
was the inability of our study to target all young Korean children 
infected with the influenza A (H1N1) virus. It did, however, tar-
get hospitalized child patients who had been confirmed as di-
agnosed with the disease, and thus it has been able to provide 
important information about the clinical patterns of Korean 
children infected with influenza A (H1N1).
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